Bill > HR2706

This bill, the Freedom from Price Gouging Act, would amend the Social Security Act to require drug manufacturers to pay a Medicare Part B rebate if the price of certain drugs increases faster than inflation. The key provisions include: - Defining "Part B rebatable drugs" as single-source drugs or biologicals paid for under Medicare Part B, with some exceptions for drugs with low average charges or vaccines. - Requiring the Secretary of Health and Human Services to report to manufacturers quarterly on the total billing units and excess price increases for their Part B rebatable drugs. - Mandating that manufacturers pay a rebate to the government equal to the amount of the excess price increase for these drugs. - Applying the rebate to the patient coinsurance amount, so that beneficiaries pay 20% of the inflation-adjusted price. - Allowing the Secretary to reduce or waive the rebate in cases of drug shortages or other exigent circumstances. - Authorizing civil monetary penalties for manufacturers that fail to pay the required rebates. - Directing the Secretary to study the feasibility of expanding the rebate system to include more types of drugs.

Business and Industry, Health and Social Services, Labor and Employment

https://www.congress.gov/bill/117th-congress/house-bill/2706/all-info